Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review (Q37960507)

26 August 2017

title

Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review (English)

1 reference

26 August 2017

main subject

metastatic breast cancer

1 reference

Alberto J Montero

1

1 reference

26 August 2017

Betsy Adams

series ordinal

2

1 reference

26 August 2017

C Marcela Diaz-Montero

series ordinal

3

1 reference

26 August 2017

Stefan Glück

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

Expert Review of Clinical Pharmacology

26 August 2017

published in

1 reference

26 August 2017

volume

4

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

329-334

1 reference

26 August 2017

cites work

Cancer statistics, 2009

1 reference

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

21 January 2018

1 reference

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

21 January 2018

1 reference

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

A systematic review of taxane-containing regimens for metastatic breast cancer

21 January 2018

1 reference

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

21 January 2018

1 reference

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

21 January 2018

1 reference

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

21 January 2018

1 reference

North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer

21 January 2018

1 reference

Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute

21 January 2018

1 reference

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

21 January 2018

1 reference

Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies

21 January 2018

1 reference

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes

21 January 2018

1 reference

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

21 January 2018

1 reference

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECP.11.7

1 reference

26 August 2017

1 reference